INTRODUCTION
============

Incidence rates of bladder cancer differ notably between men and women. The estimated numbers of new bladder cancer cases in 2020 in the United States will be approximately 62,100 and 19,300 for men and women, respectively \[[@r1]\]. Smoking and occupational exposure to aromatic amines are the most established risk factors for bladder cancer \[[@r2]\], which are unlikely to fully explain discrepancies in incidence of bladder cancer between men and women.

Animal and human-cell preclinical studies have indicated that steroid hormone receptor signaling plays an important role in bladder cancer development and progression \[[@r3]--[@r5]\]. Emerging observational studies have investigated the potential relationship between hormonal and reproductive factors and bladder cancer risk in women with inconsistent results \[[@r6]--[@r9]\]. Understanding the effects of hormonal and reproductive factors on bladder cancer risk may contribute to its early detection, potentially improving prognosis. The objectives of this study were, therefore, to assess the association between hormones and reproductive factors and the risk of bladder cancer using data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort, and to perform a meta-analysis based on all available prospective studies.

RESULTS
=======

After a median of 11.6 years of follow-up, 237 incident bladder cancer cases were identified in PLCO cohort. [Table 1](#t1){ref-type="table"} shows the baseline participant characteristics according to occurrence of bladder cancer. Generally, bladder cancer cases were older, less educated, more often of white race, and much more likely to be ever smokers, compared to non-cases. There was little difference in other characteristics, including BMI, marital status, alcohol drinking habits and family history of cancer, between the two groups.

###### Baseline participant characteristics according to bladder cancer occurrence in the PLCO cohort.

  --------------------------------- -------------------------- ------------------- -------------
  **Variables**                     **Non-cases (n=70,347)**   **Cases (n=237)**   **p-value**
  Control group (n, %)              35,129 (49.9%)             115 (48.5%)         0.664
  Age (years), mean (SD)            62.47 ± 5.38               63.77 ± 5.15        \<0.001
  Smoking status (n, %)                                                            \<0.001
  Never                             39,485 (56.1%)             79 (33.3%)          
  Current                           6,718 (9.5%)               48 (20.3%)          
  Former                            24,135 (34.3%)             110 (46.4%)         
  Missing                           9 (0.0%)                   0 (0.0%)            
  Education (n, %)                                                                 0.020
  ≤High school                      33,063 (47.0%)             127 (53.6%)         
  ≥Some college                     37,108 (52.7%)             108 (45.6%)         
  Missing                           176 (0.3%)                 2 (0.8%)            
  Body mass index (n, %)                                                           0.617
  \<25.0 kg/m2                      27,984 (39.8%)             101 (42.6%)         
  ≥25.0 kg/m2                       41,354 (58.8%)             132 (55.7%)         
  Missing                           1,009 (1.4%)               4 (1.7%)            
  Race (n, %)                                                                      0.014
  White, Non-Hispanic               62,207 (88.4%)             224 (94.5%)         
  Other                             8,114 (11.5%)              13 (5.5%)           
  Missing                           26 (0.0%)                  0 (0.0%)            
  Marital status (n, %)                                                            0.083
  Married                           48,590 (69.1%)             156 (65.8%)         
  Not married                       21,601 (30.7%)             79 (33.3%)          
  Missing                           156 (0.2%)                 2 (0.8%)            
  Family history of cancer (n, %)   41,515 (59.2%)             145 (61.4%)         0.490
  Alcohol drinking status (n, %)                                                   0.277
  Never                             7,493 (10.7%)              21 (8.9%)           
  Former                            7,937 (11.3%)              22 (9.3%)           
  Current                           38,340 (54.5%)             144 (60.8%)         
  Missing                           16,577 (23.6%)             50 (21.1%)          
  --------------------------------- -------------------------- ------------------- -------------

PLCO, prostate, lung, colorectal and ovarian; SD, standard deviation

[Table 2](#t2){ref-type="table"} shows the HRs for bladder cancer according to hormonal and reproductive factors in the PLCO cohort. Early menopause (\< 45 years) was positively but not significantly associated with bladder cancer risk, compared with menopause at 50-54 years (adjusted HR 1.25, 95% CI 0.91-1.71; p = 0.176). A nonsignificant elevation in risk for bladder cancer was found in women with HRT use compared with non-users (adjusted HR 1.32, 95% CI 0.99-1.76; p = 0.057), with the greatest risk in women who reported HRT use ≥ 10 years (adjusted HR 1.50, 95% CI 1.08-2.09; p = 0.017). Neither the use of oral contraceptive (OC) nor the duration of OC use was related to bladder cancer risk. No significant associations were observed for history of hysterectomy or oophorectomy. However, a borderline statistically significant inverse association was observed for women who underwent hysterectomy at age ≥ 50 years compared with women who had hysterectomy at age \< 40 years (adjusted HR 0.46, 95% CI 0.21-1.00; p = 0.051). There was no significant association between bladder cancer and age at menarche, parity, age at first birth, number of live births, stillbirth, and miscarriages, either in crude or multivariable-adjusted analyses. All of above associations were not modified by smoking status (p for interaction \> 0.05).

###### Association between hormonal and reproductive factors and bladder cancer risk in the PLCO cohort.

  ---------------------------- ---------------- --------------- ---------------------------- ---------------------------------------
  **Factors**                  **Cohort (n)**   **Cases (n)**   **Crude HR (95% CI), *p***   **Multi-adjusted HR (95% CI)\*, *p***
  Age at menarche, y                                                                         
  ≤11                          14,263           50              Reference                    Reference
  12--13                       37,820           119             0.88 (0.64-1.23), p=0.467    0.86 (0.62-1.20), p=0.386
  14--15                       15,101           54              1.00 (0.68-1.47), p=0.998    0.95 (0.64-1.40), p=0.787
  ≥16                          3,206            13              1.15 (0.62-2.11), p=0.656    1.09 (0.59-2.00), p=0.794
  Parity                                                                                     
  Nulliparous                  6,452            20              Reference                    Reference
  Parous                       64,021           217             1.07 (0.68-1.69), p=0.768    1.03 (0.65-1.63), p=0.903
  No. of live births                                                                         
  0                            6,452            20              Reference                    Reference
  1--2                         21,892           72              1.05 (0.64-1.73), p=0.833    1.05 (0.64-1.72), p=0.849
  3--4                         29,254           102             1.09 (0.68-1.77), p=0.714    1.04 (0.64-1.68), p=0.873
  ≥5                           12,875           43              1.05 (0.62-1.78), p=0.863    0.97 (0.57-1.65), p=0.904
  Age at first live birth, y                                                                 
  \<20                         12,059           36              0.81 (0.56-1.17), p=0.256    0.77 (0.53-1.13), p=0.177
  20--24                       32,763           126             Reference                    Reference
  25--29                       14,113           40              0.73 (0.51-1.04), p=0.083    0.76 (0.53-1.08), p=0.127
  ≥30                          4,868            13              0.69 (0.39-1.22), p=0.205    0.73 (0.41-1.30), p=0.284
  Ever had stillbirth                                                                        
  0                            66,986           230             Reference                    Reference
  1                            2,478            5               0.60 (0.25-1.45), p=0.256    0.56 (0.23-1.36), p=0.203
  ≥2                           598              2               1.03 (0.26-4.15), p=0.965    1.02 (0.25-4.09), p=0.983
  No. of miscarriages                                                                        
  0                            46,249           153             Reference                    Reference
  1                            15,520           56              1.09 (0.80-1.48), p=0.586    1.07 (0.78-1.45), p=0.682
  ≥2                           8,575            28              0.99 (0.66-1.48), p=0.965    0.94 (0.63-1.40), p=0.751
  Age at menopause, y                                                                        
  \<45                         19,607           76              1.32 (0.96-1.81), p=0.088    1.25 (0.91-1.71), p=0.176
  45--49                       16,675           57              1.14 (0.81-1.60), p=0.457    1.08 (0.77-1.52), p=0.658
  50--54                       25,748           78              Reference                    Reference
  ≥55                          7,942            25              1.04 (0.66-1.62), p=0.88     1.14 (0.73-1.80), p=0.557
  Type of Menopause                                                                          
  Natural Menopause            43,571           151             Reference                    Reference
  Surgery                      23,314           80              1.02 (0.77-1.33), p=0.907    1.06 (0.81-1.39), p=0.666
  Drug Therapy                 2,325            4               0.50 (0.19-1.35). p=0.171    0.59 (0.22-1.60). p=0.301
  History of hysterectomy                                                                    
  No                           45,410           153             Reference                    Reference
  Yes                          25,000           84              1.02 (0.78-1.34), p=0.866    1.05 (0.80-1.37), p=0.738
  Age at hysterectomy, y                                                                     
  \<40                         8,780            31              Reference                    Reference
  40--44                       6,121            23              1.06 (0.62-1.81), p=0.837    1.02 (0.59-1.76), p=0.939
  45--49                       5,164            22              1.19 (0.69-2.05), p=0.537    1.20 (0.69-2.08), p=0.515
  ≥50                          4,843            8               0.46 (0.21-1.01), p=0.052    0.46 (0.21-1.00), p=0.051
  Oophorectomy status                                                                        
  No                           55,379           190             Reference                    Reference
  Yes                          13,936           42              0.92 (0.66-1.28), p=0.608    0.92 (0.66-1.29), p=0.631
  OC use                                                                                     
  Never                        32,178           112             Reference                    Reference
  Ever                         38,279           125             0.95 (0.74-1.23), p=0.711    1.07 (0.81-1.40), p=0.639
  Duration of OC use, y                                                                      
  Never                        32,166           112             Reference                    Reference
  1--3                         17,862           62              1.01 (0.74-1.38), p=0.939    1.13 (0.82-1.56), p=0.471
  4--5                         5,205            13              0.73 (0.41-1.30), p=0.286    0.87 (0.48-1.55), p=0.628
  6--9                         6,300            22              1.02 (0.64-1.61), p=0.940    1.15 (0.72-1.84), p=0.554
  ≥10                          8,835            27              0.89 (0.58-1.35), p=0.586    0.96 (0.62-1.48), p=0.850
  HRT use                                                                                    
  Never                        22,921           69              Reference                    Reference
  Ever                         47,062           168             1.18 (0.89-1.56), p=0.243    1.32 (0.99-1.76), p=0.057
  Duration of HRT use, y                                                                     
  Never                        22,921           69              Reference                    Reference
  ≤5                           21,299           74              1.14 (0.82-1.59), p=0.425    1.30 (0.93-1.81), p=0.125
  6--9                         8,668            20              0.76 (0.46-1.24), p=0.271    0.92 (0.55-1.53), p=0.740
  ≥10                          17,095           74              1.45 (1.05-2.02), p=0.026    1.50 (1.08-2.09), p=0.017
  ---------------------------- ---------------- --------------- ---------------------------- ---------------------------------------

\*Adjusted for age (categorical), race (non-Hispanic white vs. Other), body mass index (\<25 kg/m^2^ vs. ≥25 kg/m^2^), education (≤high school vs. ≥some college), and smoking status (never vs. former ≤ 15 years since quit vs. former \> 15 years since quit vs. former year since quit unknown vs. current smoker ≤ 1 pack per day vs. current smoker \>1 pack per day vs. current smoker intensity unknown).

PLCO, prostate, lung, colorectal and ovarian; HR, hazard ratio; CI, confidence interval; y, year; No., number; OC, oral contraceptive; HRT, hormone replacement therapy.

[Figure 1](#f1){ref-type="fig"} shows risk estimates of the association between bladder cancer and reproductive and hormonal factors in the meta-analysis. We can see that parous women had significantly lower bladder cancer risk than nulliparous women (pooled HR 0.79, 95% CI 0.73-0.86; [Figure 1A](#f1){ref-type="fig"}). No significant heterogeneity was observed between the study-specific HRs overall (p for heterogeneity = 0.966). In addition, we observed a significant association between menopause at an earlier age and bladder cancer risk (pooled HR 1.22, 95% CI 1.06-1.40; [Figure 1B](#f1){ref-type="fig"}) without obvious heterogeneity between studies (p for heterogeneity = 0.283). No significant association was found for any use of hormone replacement therapy (HRT) (pooled HR 1.02, 95% CI 0.91-1.16; [Figure 1C](#f1){ref-type="fig"}). However, women who used estrogen-progestogen therapy (EPT) for HRT experienced a no significantly lower risk than those who never used HRT (pooled HR 0.79, 95% CI 0.59-1.06; [Figure 1D](#f1){ref-type="fig"}).

![**Forest plots showing risk estimates of the association between bladder cancer and reproductive and hormonal factors.** Risk estimates for bladder cancer and parity (**A**); early menopause (**B**); any use of hormone replacement therapy (**C**); use of estrogen-progestogen therapy for hormone replacement therapy (**D**). The square denotes the weight size of each included study and the diamond represents the pooled HR (95% CI).](aging-12-103523-g001){#f1}

DISCUSSION
==========

In this meta-analysis based on the PLCO cohort and seven previously published prospective studies, we observed a higher risk of bladder cancer among nulliparous women compared with parous women and among women who experienced early menopause. No association was observed for any use of HRT, although a no significantly lower risk was found among women using EPT.

Although the findings of PLCO cohort did not support an inverse association between parity and bladder cancer, parity has been shown to be negatively associated with bladder cancer risk in various observational studies \[[@r7]--[@r11]\]. Most of these studies did not find a downward trend in risk with increasing number of births, which indicated that there may be a threshold effect in which the protective mechanism underlying parity was established after the first birth. Pregnant women experience dramatic increases in estrogen and progesterone levels; however, the exact mechanisms through which estrogen and progesterone affect lifetime bladder cancer risk remain unclear. Hoffman et al. \[[@r12]\] found that raloxifene inhibited growth of bladder cancer cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Estrogen receptor alpha (ERα) was shown to play a protective role in bladder cancer through circ_0023642/miR-490-5p/EGFR signaling \[[@r13]\]. Studies using bladder cancer tissue specimens have demonstrated that elevated or reduced expression of estrogen and progesterone receptors as well as alterations of their upstream or downstream pathways are associated with clinical outcomes \[[@r14], [@r15]\].

Early age at menopause has been associated with a higher risk of bladder cancer in several previous cohort studies \[[@r6], [@r11], [@r16]\] and the present PLCO cohort, although not all associations were statistically significant. In addition, we observed a over 50% decrease in risk for bladder cancer among women who reported age at hysterectomy ≥50 years compared with women who reported age at hysterectomy \<40 years in the PLCO cohort, which indirectly supported that early age at menopause was associated with an increased risk of bladder cancer. Of note, this finding could be confounded by smoking status as a previous study showed that smoking women experience an earlier age at menopause than non-smokers \[[@r17]\]. However, in this analysis the result did not differ after adjusting for smoking status.

Many prospective studies, including the PLCO cohort, have either found a null association or a positive association between bladder cancer and HRT \[[@r6], [@r11], [@r16]\]. Findings from our meta-analysis based on seven cohort studies suggested that HRT was not related to the risk of bladder cancer. However, a few previous cohort studies have indicated that bladder cancer risk may differ by formulation and reported a potential inverse association with EPT use \[[@r8], [@r9]\]. Therefore, we also performed a meta-analysis and found that EPT was negatively but not significantly associated with bladder cancer. McGrath et al. \[[@r18]\] reported in 2006 that women who used EPT for HRT experienced a no significantly lower risk than those who never used HRT in the Nurses' Health Study (NHS) cohort. However, an updated NHS study in 2020 failed to find an inverse association between EPT and bladder cancer risk with ten years of additional follow-up and double the number of cases \[[@r6]\]. Therefore, the association between EPT and bladder cancer is still unclear and should be further examined in future prospective studies.

Strengths of the PLCO study included the large size, the population-based setting, a comprehensive list of potential confounders, and a virtually complete follow-up. Strengths of our meta-analysis included the strict inclusion criteria (restriction to prospective studies), the large sample size, and the homogeneity across eligible studies. Several limitations should also be mentioned. First, only baseline exposure data were used in the PLCO analysis and thus we were not able to take into account change in exposure status over time. Second, the results were still potentially biased by residual confounding after multi-adjustment. In the PLCO cohort, we could not adjust our results for exposures to chemicals and physical activity. Third, a meta-analysis is unable to solve problems with confounding variables that could be inherent in the original studies and inadequate control of all known confounders may bias the summary results. Finally, the PLCO and meta-analysis have some contradicting results. For example, menopause at an earlier age was significantly associated with a higher risk of bladder cancer in the meta-analysis. On the other hand, an earlier menopause was positively but not significantly associated with bladder cancer risk in the PLCO cohort, which may have limited sample size and statistical power compared with a meta-analysis.

In conclusion, our study indicated an elevation in risk for bladder cancer among nulliparous women and among women who reported earlier age at menopause. The underlying mechanisms that may be responsible for these relationships remain to be determined.

MATERIALS AND METHODS
=====================

Subjects and study design
-------------------------

The design and methods of the PLCO screening trial have been published \[[@r19]\]. Briefly, the PLCO study is a large-scale clinical trial designed to determine whether certain screening tests reduce death from prostate, lung, colorectal, and ovarian cancer. A total of 154,897 eligible participants between 55 and 74 years were enrolled into the PLCO trial at 10 clinical screening centers throughout the United States between November 1993 and July 2001. Reproductive and hormonal factors, including age at menarche, number of live-born children, age at first birth, age at menopause, reason for menopause, hysterectomy status, oophorectomy status, OC use, and HRT, were ascertained on the baseline questionnaire. Age, sex, race, education, marital status, smoking status, family history of cancer, height, and weight were also collected in the baseline questionnaire. PLCO study was approved by the institutional review boards of the National Cancer Institute and each of the participating centers. Informed consent was obtained from each eligible participant in the study.

Subject selection and bladder cancer case ascertainment
-------------------------------------------------------

In this study, participants were excluded if they were male (n = 76,682); had not returned a baseline questionnaire (n = 2,094); had reported a previous cancer at baseline (n = 5,168); had died of an unknown cause or had an undetermined case status (n = 36); or did not have follow-up time (n = 333). Thus, the cohort for analysis consisted of 70,584 women.

Incident cases of primary carcinoma of the urinary bladder were updated annually using a self-reported questionnaire. Participants were asked whether they had been diagnosed with any cancer, cancer types, and diagnosis date in the previous year. State registries, death certificates and physician reports were examined as additional sources of cancer incidence data. Cancer diagnoses were verified through medical record abstraction. Participants were followed until cancer diagnosis or death, or end of follow-up (December 31, 2009).

Statistical analysis
--------------------

A multivariate Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Models were adjusted for potential confounders including age (categorical), race (non-Hispanic White vs. Other), body mass index (BMI, \< 25 kg/m^2^ vs. ≥ 25 kg/m^2^), education (≤ high school vs. ≥ some college), and smoking status (never vs. former ≤ 15 years since quit vs. former \> 15 years since quit vs. former year since quit unknown vs. current smoker ≤ 1 pack per day vs. current smoker \> 1 pack per day vs. current smoker intensity unknown). Tests of multiplicative interaction were performed using likelihood-ratio tests compared models with and without the interaction term. The proportional hazards (PH) assumption was examined using the Schoenfeld residual test \[[@r20]\].

Meta-analysis
-------------

Literature search: A comprehensive literature search and selection was performed in PubMed through February 2020 by two independent reviewers (X.X. and B.L.).

Inclusion criteria
------------------

(*i*) investigated the associations between hormonal and/or reproductive exposures and bladder cancer risk, (*ii*) risk estimates with their 95 % CIs were given or sufficient information was provided for calculation, and (*iii*) the study design was cohort, nested case-control, case-cohort or clinical trial. Seven previously published prospective studies \[[@r6]--[@r11], [@r16]\] and the PLCO cohort were finally included in the meta-analysis.

Statistical methods
-------------------

We analyzed the effects of ever versus never exposure to parity, age at menopause, use of any HRT, and use of EPT for HRT on bladder cancer risk using a meta-analysis approach, because these associations reported in published literature were inconsistent. If a single study reported results for different exposures (e.g., different number of births) but did not report the overall results, we combined the corresponding estimates using the methods proposed by Hamling et al. \[[@r21]\], taking into account the correlation between estimates. A random effects model \[[@r22]\] was used to calculate summary HRs and 95 % CIs. Heterogeneity among studies was assessed by the Q test and I^2^. All statistical analyses were performed using the software STATA version 15 (Stata Corp, College Station, TX, USA). A two-sided P-value \<0.05 was considered significant.
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